No one should have to decide between purchasing the insulin they need to survive and putting food on the table.
Philanthropy News Digest and NonProfit Times recently covered Helmsley’s new partnership with the Civica Foundation, in which Helmsley is committing $5 million to support manufacturing and distribution of insulins which will be available at significantly lower prices than the current insulins on the market. Crucially, Civica cuts out the middlemen and pipeline profiteers. This is a transformative step in reducing the cost of this vital medicine and furthering our commitment to improving the lives of those living with Type 1 diabetes.
We are proud to join other bold leaders in the philanthropy sector who share a common mission of improving the overall health and wellbeing of individuals living with insulin-dependent diabetes by ensuring equitable access to insulin.
Contingent on FDA approval, Civica anticipates that the first insulin (glargine) will be available for purchase as soon as early 2024.
Learn more here: https://bit.ly/3vAQ7zp.